Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

Craig P. Carden, Debashis Sarker, Sophie Postel-Vinay, Timothy A. Yap, Gerthardt Attard, Udai Banerji, Michelle D. Garrett, George Thomas, Paul Workman, Stan B. Kaye, Johann S. de Bono

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Anticancer drug development remains slow, costly and inefficient. One way of addressing this might be the use of predictive biomarkers to select patients for Phase I/II trials. Such biomarkers, which predict response to molecular-targeted agents, have the potential to enrich these trials with patients more likely to benefit. Doing so could maximize the efficiency of anticancer drug development by facilitating earlier clinical qualification of predictive biomarkers and generating valuable information on cancer biology. In this review, we suggest a new model of early clinical trial design, which incorporates patient selection through predictive molecular biomarkers for selected targeted agents.

Original languageEnglish (US)
Pages (from-to)88-97
Number of pages10
JournalDrug Discovery Today
Volume15
Issue number3-4
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Patient Selection
Biomarkers
Pharmaceutical Preparations
Clinical Trials
Neoplasms

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Carden, C. P., Sarker, D., Postel-Vinay, S., Yap, T. A., Attard, G., Banerji, U., ... de Bono, J. S. (2010). Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discovery Today, 15(3-4), 88-97. https://doi.org/10.1016/j.drudis.2009.11.006

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? / Carden, Craig P.; Sarker, Debashis; Postel-Vinay, Sophie; Yap, Timothy A.; Attard, Gerthardt; Banerji, Udai; Garrett, Michelle D.; Thomas, George; Workman, Paul; Kaye, Stan B.; de Bono, Johann S.

In: Drug Discovery Today, Vol. 15, No. 3-4, 02.2010, p. 88-97.

Research output: Contribution to journalArticle

Carden, CP, Sarker, D, Postel-Vinay, S, Yap, TA, Attard, G, Banerji, U, Garrett, MD, Thomas, G, Workman, P, Kaye, SB & de Bono, JS 2010, 'Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?', Drug Discovery Today, vol. 15, no. 3-4, pp. 88-97. https://doi.org/10.1016/j.drudis.2009.11.006
Carden, Craig P. ; Sarker, Debashis ; Postel-Vinay, Sophie ; Yap, Timothy A. ; Attard, Gerthardt ; Banerji, Udai ; Garrett, Michelle D. ; Thomas, George ; Workman, Paul ; Kaye, Stan B. ; de Bono, Johann S. / Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. In: Drug Discovery Today. 2010 ; Vol. 15, No. 3-4. pp. 88-97.
@article{14950a554e3246c5b03b7ab5e4802628,
title = "Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?",
abstract = "Anticancer drug development remains slow, costly and inefficient. One way of addressing this might be the use of predictive biomarkers to select patients for Phase I/II trials. Such biomarkers, which predict response to molecular-targeted agents, have the potential to enrich these trials with patients more likely to benefit. Doing so could maximize the efficiency of anticancer drug development by facilitating earlier clinical qualification of predictive biomarkers and generating valuable information on cancer biology. In this review, we suggest a new model of early clinical trial design, which incorporates patient selection through predictive molecular biomarkers for selected targeted agents.",
author = "Carden, {Craig P.} and Debashis Sarker and Sophie Postel-Vinay and Yap, {Timothy A.} and Gerthardt Attard and Udai Banerji and Garrett, {Michelle D.} and George Thomas and Paul Workman and Kaye, {Stan B.} and {de Bono}, {Johann S.}",
year = "2010",
month = "2",
doi = "10.1016/j.drudis.2009.11.006",
language = "English (US)",
volume = "15",
pages = "88--97",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "3-4",

}

TY - JOUR

T1 - Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

AU - Carden, Craig P.

AU - Sarker, Debashis

AU - Postel-Vinay, Sophie

AU - Yap, Timothy A.

AU - Attard, Gerthardt

AU - Banerji, Udai

AU - Garrett, Michelle D.

AU - Thomas, George

AU - Workman, Paul

AU - Kaye, Stan B.

AU - de Bono, Johann S.

PY - 2010/2

Y1 - 2010/2

N2 - Anticancer drug development remains slow, costly and inefficient. One way of addressing this might be the use of predictive biomarkers to select patients for Phase I/II trials. Such biomarkers, which predict response to molecular-targeted agents, have the potential to enrich these trials with patients more likely to benefit. Doing so could maximize the efficiency of anticancer drug development by facilitating earlier clinical qualification of predictive biomarkers and generating valuable information on cancer biology. In this review, we suggest a new model of early clinical trial design, which incorporates patient selection through predictive molecular biomarkers for selected targeted agents.

AB - Anticancer drug development remains slow, costly and inefficient. One way of addressing this might be the use of predictive biomarkers to select patients for Phase I/II trials. Such biomarkers, which predict response to molecular-targeted agents, have the potential to enrich these trials with patients more likely to benefit. Doing so could maximize the efficiency of anticancer drug development by facilitating earlier clinical qualification of predictive biomarkers and generating valuable information on cancer biology. In this review, we suggest a new model of early clinical trial design, which incorporates patient selection through predictive molecular biomarkers for selected targeted agents.

UR - http://www.scopus.com/inward/record.url?scp=75149113069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149113069&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2009.11.006

DO - 10.1016/j.drudis.2009.11.006

M3 - Article

C2 - 19961955

AN - SCOPUS:75149113069

VL - 15

SP - 88

EP - 97

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 3-4

ER -